WOBURN, Mass. , Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA). As a Proud Sponsor NeuroMetrix will support the NFA’s mission to provide education, support, and advocacy for
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NASDAQ : NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 13,800 shares of Series C convertible preferred stock at
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NASDAQ : NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 21,300 shares of Series C convertible preferred stock at
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (" NeuroMetrix" or the "Company") ( NASDAQ : NURO, NUROW) announced today the pricing of a public offering with expected gross proceeds from the offering of $26.5 million . The offering was priced at $0.70 per share of the Company's common stock
NeuroMetrix Announces $5 Million Preferred Stock Placement WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 4, 2013-- NeuroMetrix, Inc. (Nasdaq:NURO) (the "Company" or "NURO"), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced that
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ: NURO) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 7,000 shares of Series F convertible preferred stock
Will not complete previously announced registered offering WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. ( NASDAQ : NURO, NUROW) announced today that it has entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO) (the "Company" or "NURO"), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, today announced
WOBURN, Mass. , April 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that, due to the public health impact of the COVID-19 pandemic and in accordance with orders issued by the Governor of the Commonwealth of Massachusetts , the Company’s 2020 Annual Meeting of
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today announced an agreement
